Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [21] A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases
    Stroelin, P.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    Tear, C. G. O'Bryan
    Staudacher, K.
    Vargas, J. E. Garcia
    Zou, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [23] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [24] Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases
    Maestre-Cutillas, R.
    Sanchez-Tornero, A. M.
    Baz-Sanz, L.
    Rubio-Fernandez, G.
    Casas-Fernandez, L.
    Romero-Otero, M.
    Perez-Iruela, J. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S652 - S652
  • [25] RADIUM-223 DICHLORIDE (RADIUM-223) FOR THE TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND SYMPTOMATIC BONE METASTASES: THE ESSENTIAL ROLE OF NURSES IN PATIENT CARE AND MANAGEMENT
    Curley, Tracy
    Arauz, Gabrielle
    Jensen, Trine
    Wahba, Mona
    Delacruz, Anthony
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E115 - E115
  • [26] Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
    Gallicchio, Rosj
    Mastrangelo, Pietro A.
    Nardelli, Anna
    Mainenti, Pier Paolo
    Colasurdo, Antonio P.
    Landriscina, Matteo
    Guglielmi, Giuseppe
    Storto, Giovanni
    TUMORI JOURNAL, 2019, 105 (05): : 367 - 377
  • [27] Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
    Parker, Chris
    Nilsson, Sten
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel J.
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Hoskin, Peter
    Bottomley, David
    Coleman, Robert Edward
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
    Nilsson, S.
    Strang, P.
    Aksnes, A. K.
    Franzen, L.
    Olivier, P.
    Pecking, A.
    Staffurth, J.
    Vasanthan, S.
    Andersson, C.
    Bruland, O. S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (05) : 678 - 686
  • [29] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [30] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345